

Pablo de Felipe

Pablo de Felipe received his PhD in Chemical Sciences (Molecular Biology) in 2000 from the Universidad Autónoma de Madrid (Spain), where he researched cancer gene therapy and participated in the first clinical trial of gene therapy in Spain (1995).

In 2001 he moved as a postdoctoral researcher to the University of St. Andrews (UK) where he worked in virology and biotechnology. There he contributed to the study of the 2A sequence and its development for protein co-expression, currently used in numerous biotechnological and biomedical applications.

Since his return to Madrid in 2008, he has been working on the regulation of biotechnological and advanced therapy medicinal products as part of the Spanish Agency of Medicines and Medical Devices (AEMPS), where he has been head of virology since 2022. He is also an expert and member of the Biologics Working Party (BWP) of the European Medicines Agency (EMA, Amsterdam), an expert of the European Pharmacopoeia (Strasbourg) and of the network of Heads of Medicines Agencies (HMA).

In 2022 he obtained a PhD in Humanities from the University of Bristol (UK) for his research on geographical ideas from antiquity to the Renaissance and the problems of their reception in modern times.